Baseline medication use is associated with COVID-19 severity in people with rheumatic …

EurekAlert! | Jul 2, 2021 at 2:00 AM
  • Due to sample size limitations, previous studies of DMARD use and COVID-19 outcomes have combined several different rheumatic diseases and medications, and investigated a single outcome- for example, the risk of hospitalization.
  • This analysis from Jeffrey Sparks, Zachary Wallace, and colleagues aimed to investigate the associations between baseline use of biologic or targeted synthetic DMARDs with a range of poor COVID-19 outcomes specifically in people with rheumatoid arthritis (RA).
  • The outcomes were scored on a scale of one to four for COVID-19 severity: 1) no hospitalization, 2) hospitalization without oxygen need, 3) hospitalization with any oxygen need or ventilation, or 4) death.